Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
Industry presentation at the AI Theatre: "eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening"
Median eyonis™ teams will be at booth #AI-18, AI Exhibition, Expo X1
SOPHIA ANTIPOLIS, France, February 24, 2025--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company"), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2.
The Median eyonis™ team will welcome interested parties at Booth #AI-18, AI Exhibition, Expo X1, from February 26 to March 1 (technical exhibits dates). The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD).
The Company recently reported that eyonis™ LCS, its AI-powered SaMD for Lung Cancer Screening met the primary endpoint with statistical significance in RELIVE, the second of two successful pivotal studies required for marketing authorizations in US and Europe (ClinicalTrials.gov identifier ID NCT06751576). RELIVE secondary endpoints results will be communicated as soon as all the statistical analyses are finalized.
The protocol and primary endpoints for the two pivotal studies, RELIVE and REALITY, were defined in accordance with discussions held with the FDA. By achieving the primary endpoints in both pivotal studies, eyonis™ LCS has successfully completed the regulatory requirements for clinical validation. Consequently, the regulatory dossiers for obtaining the U.S. 510(k) and European CE marking of eyonis™ LCS will be submitted to the agencies in the second quarter of this year.
"The recently reported pivotal study results suggest eyonis™ LCS may enable broad implementation of LDCT lung cancer screening procedures by improving lung cancer diagnosis accuracy and addressing the bottlenecks of complexity and time required for analyzing LDCT images," said Thomas Bonnefont, COO and CCO of the eyonis™ Business Unit at Median Technologies. "Based on our strong pivotal results, we are now looking towards our filings for marketing authorizations, in both the US and Europe, in Q2 2025, as soon as we finish the analysis. We will report RELIVE secondary endpoints results in the coming weeks. In the interim, we are very pleased to share the eyonis™ LCS pivotal study results already available, and discuss the game changing potential of our Software as a Medical Device with the radiology community at the European Congress of Radiology", Thomas Bonnefont added.
Median's eyonis™ team will present at ECR:
Industry Presentation: "eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening" Presenter: Valérie Bourdès, MD, VP Clinical and Medical Affairs, eyonis™ - Median TechnologiesSession AI-IND 3 - AI Lightning Talks 3Wednesday, February 26 - 13:30 – 14:30 CETAI Theatre, ACV Building Level -2
Concurrently, Median's iCRO team will present:
Research Presentation : "Discord Dilemmas in Lung Cancer Clinical Trials: Navigating Reader Variability in Response Assessment" Author: Hubert Beaumont, Lead Scientist, Median TechnologiesResearch Presentation Session: Oncologic ImagingSession: RPS 116 - Staging, metastases and response assessmentWednesday, February 26 – 8:00 – 9:30 CETACV Building, Research Stage 3
About eyonis™ LCS: eyonis™ Lung Cancer Screening (LCS) is an AI/ML-enabled Software as a Medical Device that uses machine learning to analyze imaging data generated with low dose computed tomography (LDCT). eyonis™ LCS aids to diagnose lung cancer at the earliest stages, when it can still be cured in many patients. eyonis™ LCS is the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY (successfully completed - Clinicaltrials.gov ID: NCT06576232) and RELIVE (primary endpoint successfully achieved, secondary endpoints analysis on-going - Clinicaltrials.gov ID: NCT06751576). Filing applications including these pivotal data are scheduled to be submitted for FDA 510(k) clearance and CE marking in Q2 2025.
About Median Technologies: Pioneering innovative imaging solutions and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.
These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224801834/en/
Contacts
MEDIAN TECHNOLOGIES Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 88emmanuelle.leygues@mediantechnologies.com
U.S. media & investors Chris MaggosCOHESION BUREAU +41 79 367 6254chris.maggos@cohesionbureau.com
Investors Ghislaine GasparettoSEITOSEI ACTIFIN +33 6 21 10 49 24ghislaine.gasparetto@seitosei-actifin.com
Press Caroline CarmagnolALIZE RP +33 6 64 18 99 59median@alizerp.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
Patero Announces Launch of CryptoQoR Post-Quantum Cryptography Software
COLLEGE PARK, Md.--(BUSINESS WIRE)-- Patero, a leader in post-quantum cryptography (PQC), today announced the launch CryptoQoR™. This new highly efficient crypto-agile software module establishes secure communication channels and proactively mitigates security risks using hybrid post-quantum encryption. The solution can be readily deployed into existing infrastructure to improve current cryptographic protection and immediately remediate risks associated with quantum attacks. Today's encryption is already obsolete. Sensitive, long-life data is being stolen every day to be decrypted tomorrow by cryptographically relevant quantum computers. The post-quantum cryptography (PQC) market is projected to grow from $302.5 million in 2024 to $1,887.9 million by 2029. 1 The approach to 'Q-day,' the day when quantum computers can be used to break traditional encryption, is accelerating with daily advances in quantum computing, quantum switching, AI, and high-performance computing. The migration to PQC is an imperative to secure sensitive data against future quantum threats. Governments and regulatory bodies have mandated the transition to PQC, which includes the adoption of post-quantum cryptographic solutions such as those offered by Patero. 'Today's encryption is already obsolete. Using Shor's algorithm, Quantum computers will decrypt data encrypted with asymmetric algorithms such as RSA or Elliptic Curve. Your data is no longer safe,' said Patero Chief Executive Officer, Crick Waters. 'Sensitive, long-life data is being stolen every day to be decrypted tomorrow by cryptographically relevant quantum computers.' Patero CryptoQoR also cloaks Internet-exposed endpoints, making it extremely difficult to find network attack surfaces while protecting businesses from quantum vulnerabilities. CryptoQoR's cloaking feature, therefore, is a key element of Zero Trust network architectures. CryptoQoR utilizes a certificateless authentication method to establish trust and authentication between endpoints. Untrusted endpoints are ignored. Only trusted endpoints, those with quantum-key authentication, are trusted to establish quantum-resistant tunnels. This zero-trust framework reduces network attack surfaces and enhances overall data security. Waters added, 'CryptoQoR is also a crypto-agile software solution. It provides software-selectable PQC algorithms, allowing users to select their preferred algorithms in situ or upgrade to new quantum-resistant algorithms without requiring product recall or equipment replacement. All cryptography is eventually broken, but CryptoQoR's agility future-safes networks.' About Patero Patero is a leader in quantum secure communications. Patero's cryptographic discovery and inventory solution quantifies risk and prioritizes mitigation of vulnerabilities against present and future cryptographic attacks. Patero's crypto-agile post-quantum security solutions hybridize classic encryption with NIST-standardized quantum-resistant encryption algorithms to mitigate cryptographic vulnerabilities and protect data-in-motion from steal-now, decrypt-later, and future direct decryption attacks. Patero is privately held and based in the Quantum Startup Foundry at the University of Maryland, College Park. For more information, visit For investment opportunities, contact company CEO Crick Waters at crick@ Learn more at 1 Quantum Cryptography Market Forecast to 2030. MarketsandMarkets. October 2024.
Yahoo
an hour ago
- Yahoo
Fungi concerns spark nationwide recall of Zicam® and Orajel™ products
(WJW) – According to the U.S. Food and Drug Administration, Church & Dwight Co., Inc. is voluntarily recalling some Zicam® and Orajel™ products because fungi could be present in the items' cotton swab components. The recalled products include all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. Consumers are advised to 'immediately' stop using the recalled products. Major grocery chain slashing prices for the summer 'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA. Brain-eating amoeba: How are people infected? Here's the specific details to check for: Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. You can view images of the recalled products in the slideshow below: 'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website. Consumers can CLICK HERE or call (800) 981-4710 for refund details. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Compliance Scorecard Releases Major Platform Upgrade with Enhanced Security Awareness Training, Risk Intelligence, and Compliance Automation
Company to Showcase Latest Innovations at Pax8 Beyond 2025 DOVER, N.H., June 09, 2025--(BUSINESS WIRE)--Compliance Scorecard™, a Compliance as a Service (CaaS) platform provider, today announced significant new features that redefine how MSPs deliver Compliance-as-a-Service (CaaS) – with real-time metrics, streamlined audit readiness and customizable client governance capabilities. "Our latest release reflects what MSPs have been asking for – less noise, more context, and real metrics that map directly to frameworks like CMMC, HIPAA, FTC Safeguards and SOC 2," said Tim Golden, Founder and CEO of Compliance Scorecard. "It's not just a checklist anymore. We're helping MSPs prove compliance with confidence." Security Awareness Training is no longer a checkbox. Frameworks including CIS Control 14 demand governance, metrics, and measurable outcomes. Compliance Scorecard is the first platform to give MSPs live SAT metrics that are tied to compliance frameworks and fully auditable. Compliance Scorecard's KPI engine allows MSPs and their clients to define custom success metrics including phishing click rate, quiz scores, or training frequency, and see progress over time. Key New Features: Security Awareness Training (SAT) Scorecard: Unified SAT dashboard and KPI tracking across Symbol Security, Huntress, CyberHoot, Phin and others. Metrics tie directly to client policies, SOPs, and user adoption, with CIS Control 14 addressed through policy-backed, real-time insights. Risk and Assessment Automation: Built-in RACI modeling (Responsible, Accountable, Consulted, Informed) for assessment events, audit-aligned evidence fields (Examine, Interview, Test), and seamless connections between control objectives and the Risk Register. Policy and Adoption Engine: Unified policy templates for MSPs and clients, exportable adoption metrics, and customizable client email workflows for user invites, policy approvals and campaign tracking. Enhanced Platform Experience: Role-based access control with collapsible dashboards with persistent settings, and a mobile-optimized Trust Center and Knowledge Base for intuitive filtering and sorting. Compliance Scorecard will showcase the new release at Pax8 Beyond 2025, offering live demos, strategy sessions, and one-on-one consultations with its compliance experts. To learn more, visit or explore the offering in the Pax8 Marketplace. About Compliance Scorecard™ Compliance Scorecard is a leader in governance, risk, and compliance solutions for Managed Service Providers (MSPs). Built with a security-by-design philosophy, the platform simplifies compliance management, empowering MSPs to grow their business while protecting clients. With features such as policy management, risk registers, asset management, and SharePoint integration, Compliance Scorecard helps MSPs manage multiple clients and scale their compliance services with ease. Follow Compliance Scorecard on YouTube, LinkedIn and Facebook. View source version on Contacts Media: Kim PegnatoLongview Strategies781-835-7118Kpegnato@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
